pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Ophthalmology · news · pharmadog
← back to Ophthalmology
News · Ophthalmology
168
stories
9d
Building Resilience for the Future of Biopharma Innovation
fiercebiotech
9d
Scholar Rock rejigs approval filing after FDA flags violations at Novo plant
biospace
9d
After tasting IPO success, Hemab’s CEO seeks ‘flavor of a multi-product coagulation company’
fiercebiotech
9d
Aura lays off 20% of workforce, rejigs C-suite amid R&D refocus on eye cancer
fiercebiotech
10d
Abbott teams with Google Health on AI-powered health insights app
fiercebiotech
10d
Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline
biospace
10d
Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push
fiercebiotech
11d
As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door
biospace
14d
Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M
biopharma dive
14d
Tarsus bets $450M on Alkeus’ Stargardt drug
endpoints
14d
Tarsus pays $450M for Alkeus and its phase 3-stage retinal disease drug
fiercebiotech
14d
Opinion: STAT+: Stop asking if AI is good for medicine
stat
15d
Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengrui
fiercebiotech
15d
Amgen’s MariTide stands alone after obesity cull while analysts seek more M&A
biospace
15d
The main therapy used for children with autism faces changes under Medicaid
stat
16d
Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO
fiercebiotech
16d
Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s Journavx
fiercebiotech
17d
Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trials
fiercebiotech
17d
BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotech
biospace
17d
Novo’s late-stage IL-6 stumble shakes inflammation space
biospace
17d
After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA company
fiercebiotech
20d
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
fiercebiotech
21d
Chutes & Ladders—Legend CEO departs without successor in place
fiercebiotech
21d
Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chest
biospace
21d
Pfizer's Phase 3 win for Litfulo; Braveheart, Attovia eye IPOs of $275M, $182M
endpoints
21d
Daiichi’s pipeline falls behind rivals as cash flow nears peak: analysts
biospace
21d
Opinion: Ten years after WHO recognition, mycetoma remains one of the world’s most neglected diseases
stat
21d
Chronically ill people face confusion over new Medicaid work rules and ‘medically frail’ exemption
stat
21d
Not-so-special delivery: When biopharmas fumble layoff news
biospace
22d
NSF testing new Ph.D. model giving trainees academic and industry experience
stat
← prev
page 2 of 6
next →
